# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Patrick Trucchio reiterates Altimmune (NASDAQ:ALT) with a Buy and maintains $12 price target.
JMP Securities analyst Jonathan Wolleben maintains Altimmune (NASDAQ:ALT) with a Market Outperform and lowers the price targ...
Cramer discusses Agnico Eagle Mines, Nutanix, Altimmune, CVR Energy and Quanta Services on CNBC's "Mad Money."
Guggenheim analyst Seamus Fernandez downgrades Altimmune (NASDAQ:ALT) from Buy to Neutral.